T cells targeted against a single minor histocompatibility antigen can cure solid tumors
Author: ["Marie-Christine Meunier","Jean-Sébastien Delisle","Julie Bergeron","Vincent Rineau","Chantal Baron","Claude Perreault"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
T cells responsive to minor histocompatibility (H) antigens are extremely effective in curing leukemia but it remains unknown whether they can eradicate solid tumors. We report that injection of CD8+ T cells primed against the immunodominant H7a minor H antigen can cure established melanomas in mice. Tumor rejection was initiated by preferential extravasation at the tumor site of interferon (IFN)-γ–producing H7a-specific T cells. Intratumoral release of IFN-γ had two crucial effects: inhibition of tumor angiogenesis and upregulation of major histocompatibility complex (MHC) class I expression on tumor cells. Despite ubiquitous expression of H7a, dissemination of a few H7a-specific T cells in extralymphoid organs caused neither graft-versus-host disease (GVHD) nor vitiligo because host nonhematopoietic cells were protected by their low expression of MHC class I. Our preclinical model yields unique insights into how minor H antigen–based immunotherapy could be used to treat human solid tumors.
Cite this article
Meunier, MC., Delisle, JS., Bergeron, J. et al. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 11, 1222–1229 (2005). https://doi.org/10.1038/nm1311